Special Issue

Nanocarriers in Mucosal Drug Delivery

Message from the Guest Editor

This Special Issue will provide a comprehensive overview of recent advances in nanocarrier-based mucosal drug delivery, ranging from fundamental mechanistic understanding to translational applications. We welcome contributions exploring the design. characterization, and functionalization of nanocarriers. Topics may include strategies for mucus penetration. mucoadhesion, and stimuli-responsive release, as well as preclinical and clinical evaluations of nanocarrier systems. By bridging mechanistic insights with applied research, this Special Issue will highlight the therapeutic potential of nanocarriers in improving treatment outcomes across a range of diseases. We invite researchers engaged in this multidisciplinary field to contribute original research articles or comprehensive reviews to this Special Issue.

Guest Editor

Dr. Hatem Hassan

Medway School of Pharmacy, University of Kent, Maritime Kent, Chatham ME4 4TB, UK

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/254841

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).